The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines

Vaccine

Volumn 28, Issue 46, 2010, Pages 7436-7443

  Feng, Feng ^a,b   Teoh, Chee Quin ^a,b   Qiao, Qiao ^a,b   Boyle, David ^c   Jilbert, Allison R ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c CSIRO   (Australia)

Author keywords

DNA vaccine; Duck hepatitis B virus (DHBV); Recombinant fowlpoxvirus (rFPV)

Indexed keywords

DNA VACCINE; ENTECAVIR; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DUCK; DUCK HEPATITIS B VIRUS; EMBRYO; FOWLPOX VIRUS; HEPATITIS B; HUMAN; LIVER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINATION;

ANIMALS; DISEASE MODELS, ANIMAL; DNA, VIRAL; DUCKS; FOWLPOX VIRUS; HEPADNAVIRIDAE INFECTIONS; HEPATITIS ANTIBODIES; HEPATITIS B VIRUS, DUCK; HEPATITIS, VIRAL, ANIMAL; HEPATOCYTES; IMMUNIZATION, SECONDARY; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 77958156535     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.091     Document Type: Article

References (37)

1. Akbar F., Yoshida O., Abe M., Hiasa Y., Onji M. Engineering immune therapy against hepatitis B virus. Hepatol Res 2007, 37(October (Suppl. 3)):S351-S356.
2. Yang J.F., Lin Y.Y., Huang J.F., Liu S.F., Chu P.Y., Hsieh M.Y., et al. Comparison of clinical application of the Abbott HBV PCR kit and the VERSANT HBV DNA 3.0 test to measure serum hepatitis B virus DNA in Taiwanese patients. Kaohsiung J Med Sci 2009, 25(August (8)):413-422.
3. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004, 64(October (1)):1-15.
4. Wright T.L. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 2004, 24(Suppl. 1):31-36.
5. van Zonneveld M., Honkoop P., Hansen B.E., Niesters H.G., Murad S.D., de Man R.A., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004, 39(March (3)):804-810.
6. Liu C.J., Kao J.H. Pegylated interferons for the treatment of chronic hepatitis B. Recent Pat Antiinfect Drug Discov 2006, 1(January (1)):85-94.
7. Lok A.S. Hepatitis B infection: pathogenesis and management. J Hepatol 2000, 32(Suppl. 1):89-97.
8. Jilbert A.R., Botten J.A., Miller D.S., Bertram E.M., Hall P.M., Kotlarski J., et al. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection. Virology 1998, 244(May (2)):273-282.
9. Foster W.K., Miller D.S., Marion P.L., Colonno R.J., Kotlarski I., Jilbert A.R. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother 2003, 47(August (8)):2624-2635.
10. Miller D.S., Kotlarski I., Jilbert A.R. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner. Virology 2006, 351(July (1)):159-169.
11. Miller D.S., Halpern M., Kotlarski I., Jilbert A.R. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection. Virology 2006, 348(May (2)):297-308.
12. Foster W.K., Miller D.S., Scougall C.A., Kotlarski I., Colonno R.J., Jilbert A.R. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection. J Virol 2005, 79(May (9)):5819-5832.
13. Saade F., Buronfosse T., Pradat P., Abdul F., Cova L. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes. Vaccine 2008, 26(September (40)):5159-5164.
14. Zimmerman K.A., Fischer K.P., Joyce M.A., Tyrrell D.L. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 2008, 82(August (16)):8013-8021.
15. Miller D.S., Boyle D., Feng F., Reaiche G.Y., Kotlarski I., Colonno R., et al. Antiviral therapy with entecavir combined with post-exposure " prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection. Virology 2008, January.
16. Triyatni M., Jilbert A.R., Qiao M., Miller D.S., Burrell C.J. Protective efficacy of DNA vaccines against duck hepatitis B virus infection. J Virol 1998, 72(January (1)):84-94.
17. Triyatni M., Ey P., Tran T., Le Mire M., Qiao M., Burrell C., et al. Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses. J Gen Virol 2001, 82(February (Pt 2)):373-378.
18. Feng F., Davis A., Lake J.A., Carr J., Xia W., Burrell C., et al. Ring finger protein ZIN interacts with human immunodeficiency virus type 1 Vif. J Virol 2004, 78(October (19)):10574-10581.
19. Pugh J.C., Di Q., Mason W.S., Simmons H. Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles. J Virol 1995, 69(August (8)):4814-4822.
20. Jilbert A.R., Wu T.T., England J.M., Hall P.M., Carp N.Z., O'Connell A.P., et al. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J Virol 1992, 66(March (3)):1377-1388.
21. Qiao M., Gowans E.J., Bailey S.E., Jilbert A.R., Burrell C.J. Serological analysis of duck hepatitis B virus infection. Virus Res 1990, 17(August (1)):3-13.
22. Boyle D.B., Coupar B.E. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res 1988, 10(June (4)):343-356.
23. Jilbert A.R., Miller D.S., Scougall C.A., Turnbull H., Burrell C.J. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology 1996, 226(December (2)):338-345.
24. Miller D.S., Bertram E.M., Scougall C.A., Kotlarski I., Jilbert A.R. Studying host immune responses against duck hepatitis B virus infection. Methods Mol Med 2004, 96:3-25.
25. Meier P., Scougall C.A., Will H., Burrell C.J., Jilbert A.R. A duck hepatitis B virus strain with a knockout mutation in the putative X ORF shows similar infectivity and in vivo growth characteristics to wild-type virus. Virology 2003, 317(December (20)):291-298.
26. Rollier C., Sunyach C., Barraud L., Madani N., Jamard C., Trepo C., et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 1999, 116(March (3)):658-665.
27. Le Mire M.F., Miller D.S., Foster W.K., Burrell C.J., Jilbert A.R. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection. J Virol 2005, 79(October (19)):12242-12252.
28. Dienstag J.L., Stevens C.E., Bhan S.C., Szmuness A.K. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann Intern Med 1982, 96:575-579.
29. Pol S., Driss F., Michel M.L., Nalpas B., Berthelot P., Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994, 344(July (8918)):342.
30. Dikici B., Kalayci A.G., Ozgenc F., Bosnak M., Davutoglu M., Ece A., et al. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 2003, 22(April (4)):345-349.
31. Beukema E.L., Brown M.P., Hayball J.D. The potential role of fowlpox virus in rational vaccine design. Expert Rev Vaccines 2006, 5(August (4)):565-577.
32. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A., et al. Boosting with recombinant vaccine increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998, 95(June (13)):7648-7653.
33. Ramsay A.J., Kent S.J., Strugnell R.A., Suhrbier A., Thomson S.A., Ramshaw I.A. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev 1999, 171(October):27-44.
34. Coupar B.E., Purcell D.F., Thomson S.A., Ramshaw I.A., Kent S.J., Boyle D.B. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 2006, 24(February (9)):1378-1388.
35. Kothlow S., Mannes N.K., Schaerer B., Rebeski D.E., Kaspers B., Schultz U. Characterization of duck leucocytes by monoclonal antibodies. Dev Comp Immunol 2005, 29(8):733-748.
36. Gares S.L., Fischer K.P., Congly S.E., Lacoste S., Addison W.R., Tyrrell D.L., et al. Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks. Clin Vaccine Immunol 2006, 13(August (8)):958-965.
37. Fischer K.P., Gares S.L., Wang D., Lorne Tyrrell D., Gutfreund K.S. Identification and characterization of functional CD154 (CD40 ligand) in the Pekin duck. Dev Comp Immunol 2007, 31(1):61-71.